Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 14/20 | 0.67 |
| ▸ | ROCK1 | Q13464 | 11/20 | 0.67 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24464193 | 0.90 | ROCK2 (0.66) | ROCK2ROCK1CCNE1CDK2 | |
| SCHEMBL24464148 | 0.89 | ROCK2 (0.53) | ROCK2ROCK1CCNE1CDK2 | |
| SCHEMBL17038115 | 0.89 | ROCK2 (0.67) | ROCK2ROCK1CCNE1CDK2 | |
| SCHEMBL24464173 | 0.84 | NPC1 (0.50) | ROCK2ROCK1CYP1A2 | |
| SCHEMBL24464163 | 0.84 | ROCK2 (0.53) | ROCK2ROCK1CCNE1CDK2 | |
| SCHEMBL20661284 | 0.82 | ROCK2 (0.71) | ROCK2ROCK1CYP1A2TDP1 | |
| SCHEMBL24862335 | 0.81 | KDR (0.44) | ROCK2ROCK1CYP1A2 | |
| SCHEMBL24464182 | 0.81 | CYP1A2 (0.48) | ROCK2ROCK1CYP1A2TDP1 | |
| SCHEMBL24353609 | 0.80 | ROCK2 (0.47) | ROCK2ROCK1CYP1A2TDP1 | |
| SCHEMBL17040778 | 0.80 | ROCK2 (1.00) | ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220395501-A1 | TREATMENT OF GVHD | KADMON CORP LLC (US) | 2022-12-15 | — | — | US | disclosed |
| US-10696660-B2 | Rho kinase inhibitors | KADMON CORPORATION, LLC (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190308953-A1 | RHO KINASE INHIBITORS | KADMON CORPORATION LLC | 2019-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696660-B2 | Rho kinase inhibitors | ROCK2, ROCK1, RHOA | ROCK2 1/4885ROCK1 2/4885MAPK8 344/4885 |
| US-20220395501-A1 | TREATMENT OF GVHD | ROCK2, ROCK1, RHOXF2 | ROCK2 1/4885ROCK1 2/4885MAPK8 2924/4885 |
| US-20190308953-A1 | RHO KINASE INHIBITORS | ROCK2, ROCK1, RHOA | ROCK2 1/4885ROCK1 2/4885MAPK8 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.